市場調查報告書

新型冠狀病毒感染疾病 (COVID-19) :開發中產品分析

Coronavirus Disease 2019 (COVID-19) - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 933874
出版日期 內容資訊 英文 1389 Pages
商品交期: 最快1-2個工作天內
價格
新型冠狀病毒感染疾病 (COVID-19) :開發中產品分析 Coronavirus Disease 2019 (COVID-19) - Pipeline Review, H1 2020
出版日期: 2020年04月23日內容資訊: 英文 1389 Pages
簡介

本報告提供新型冠狀病毒感染疾病(COVID-19)的開發中的治療藥相關全面性資訊,刊載了包含各開發階段,各藥物標的,各作用機制(MoA),各給藥途徑(RoA),各分子類型的分析。這個指南,網羅治療藥的藥理作用的說明,其完全研究開發履歷,最新的新聞和新聞稿。

簡介

  • 調查範圍

新型冠狀病毒感染疾病 (COVID-19) - 概要

新型冠狀病毒感染疾病 (COVID-19) - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 各大學、研究機關的開發平台趨勢
  • 企業開發中的產品
  • 在大學、研究機關開發中的產品

新型冠狀病毒感染疾病 (COVID-19) - 治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

新型冠狀病毒感染疾病 (COVID-19)的治療藥開發企業

  • 4D Pharma Plc
  • A2A Pharmaceuticals Inc
  • AbCellera Biologics Inc
  • Adaptive Biotechnologies Corp
  • AIM ImmunoTech Inc
  • Akers Biosciences Inc
  • Akston Biosciences Corp
  • Aldeyra Therapeutics Inc
  • Zucero Therapeutics Ltd

藥物簡介

新型冠狀病毒感染疾病 (COVID-19) - 產品開發里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC12188IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coronavirus Disease 2019 (COVID-19) - Pipeline Review, H1 2020, provides an overview of the Coronavirus Disease 2019 (COVID-19) (Infectious Disease) pipeline landscape.

Coronaviruses* are* a* group* of* viruses* belonging* to* the* family* Coronaviridae. These viruses cause respiratory infections ranging from the common cold to severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). *The most common symptoms are fever, tiredness, and dry cough. The virus is thought to spread mainly from person-to-person who are in close contact with one another and through respiratory droplets produced when an infected person coughs or sneezes.

Report Highlights:

Global Markets Direct's ‘Pharmaceutical and Healthcare latest pipeline guide Coronavirus Disease 2019 (COVID-19) - Pipeline Review, H1 2020’, provides comprehensive information on the therapeutics under development for Coronavirus Disease 2019 (COVID-19) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coronavirus Disease 2019 (COVID-19) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Coronavirus Disease 2019 (COVID-19) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 29, 34, 3, 30, 111, 164 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 6, 1, 1, 25 and 29 molecules, respectively.

Coronavirus Disease 2019 (COVID-19) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Coronavirus Disease 2019 (COVID-19) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Coronavirus Disease 2019 (COVID-19) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Coronavirus Disease 2019 (COVID-19) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Coronavirus Disease 2019 (COVID-19) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Coronavirus Disease 2019 (COVID-19) (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Coronavirus Disease 2019 (COVID-19) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Coronavirus Disease 2019 (COVID-19) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Coronavirus Disease 2019 (COVID-19) - Overview
    • Coronavirus Disease 2019 (COVID-19) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Coronavirus Disease 2019 (COVID-19) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Coronavirus Disease 2019 (COVID-19) - Companies Involved in Therapeutics Development
    • 4D Pharma Plc
    • A2A Pharmaceuticals Inc
    • AbCellera Biologics Inc
    • Adaptive Biotechnologies Corp
    • AIM ImmunoTech Inc
    • Akers Biosciences Inc
    • Akston Biosciences Corp
    • Aldeyra Therapeutics Inc
    • Zucero Therapeutics Ltd
  • Coronavirus Disease 2019 (COVID-19) - Drug Profiles
    • (ASC-09 + ritonavir) - Drug Profile
    • (emtricitabine + tenofovir disoproxil fumarate) - Drug Profile
    • acalabrutinib maleate - Drug Profile
    • ADX-629 - Drug Profile
    • AKS-446 - Drug Profile
    • AlloStim - Drug Profile
    • Ampion - Drug Profile
    • anakinra - Drug Profile
    • Antibodies 1 for Coronavirus Disease 2019 (COVID-19) - Drug Profile
    • Antibodies for Coronavirus Disease 2019 (COVID-19) - Drug Profile
  • Coronavirus Disease 2019 (COVID-19) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Coronavirus Disease 2019 (COVID-19), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Coronavirus Disease 2019 (COVID-19) - Pipeline by 4D Pharma Plc, H1 2020
  • Coronavirus Disease 2019 (COVID-19) - Pipeline by A2A Pharmaceuticals Inc, H1 2020
  • Coronavirus Disease 2019 (COVID-19) - Pipeline by AbCellera Biologics Inc, H1 2020
  • Coronavirus Disease 2019 (COVID-19) - Pipeline by Adaptive Biotechnologies Corp, H1 2020
  • Coronavirus Disease 2019 (COVID-19) - Pipeline by AIM ImmunoTech Inc, H1 2020
  • Coronavirus Disease 2019 (COVID-19) - Pipeline by Akers Biosciences Inc, H1 2020

List of Figures

  • Number of Products under Development for Coronavirus Disease 2019 (COVID-19), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020